Literature DB >> 10749560

Conditionally replicating herpes vectors for cancer therapy.

R L Martuza1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10749560      PMCID： PMC382984          DOI： 10.1172/JCI9744

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  28 in total

1.  Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma.

Authors:  A Chahlavi; T Todo; R L Martuza; S D Rabkin
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

2.  Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant.

Authors:  D J Goldstein; S K Weller
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

3.  Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.

Authors:  G Coukos; A Makrigiannakis; S Montas; L R Kaiser; T Toyozumi; I Benjamin; S M Albelda; S C Rubin; K L Molnar-Kimber
Journal:  Cancer Gene Ther       Date:  2000-02       Impact factor: 5.987

4.  Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy.

Authors:  T Todo; S D Rabkin; A Chahlavi; R L Martuza
Journal:  Hum Gene Ther       Date:  1999-11-20       Impact factor: 5.695

5.  Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus.

Authors:  T Todo; S D Rabkin; P Sundaresan; A Wu; K R Meehan; H B Herscowitz; R L Martuza
Journal:  Hum Gene Ther       Date:  1999-11-20       Impact factor: 5.695

6.  Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207.

Authors:  J R Walker; K G McGeagh; P Sundaresan; T J Jorgensen; S D Rabkin; R L Martuza
Journal:  Hum Gene Ther       Date:  1999-09-01       Impact factor: 5.695

7.  Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207).

Authors:  D A Kooby; J F Carew; M W Halterman; J E Mack; J R Bertino; L H Blumgart; H J Federoff; Y Fong
Journal:  FASEB J       Date:  1999-08       Impact factor: 5.191

8.  Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses.

Authors:  K Ikeda; T Ichikawa; H Wakimoto; J S Silver; T S Deisboeck; D Finkelstein; G R Harsh; D N Louis; R T Bartus; F H Hochberg; E A Chiocca
Journal:  Nat Med       Date:  1999-08       Impact factor: 53.440

9.  Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture.

Authors:  J Chou; E R Kern; R J Whitley; B Roizman
Journal:  Science       Date:  1990-11-30       Impact factor: 47.728

10.  Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice.

Authors:  A Chahlavi; S Rabkin; T Todo; P Sundaresan; R Martuza
Journal:  Gene Ther       Date:  1999-10       Impact factor: 5.250
View more
  21 in total

Review 1.  Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer.

Authors:  T Hermiston
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

2.  A herpes simplex virus type 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals.

Authors:  I Mohr; D Sternberg; S Ward; D Leib; M Mulvey; Y Gluzman
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

3.  Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.

Authors:  T Todo; R L Martuza; S D Rabkin; P A Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

4.  Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells.

Authors:  S Taneja; J MacGregor; S Markus; S Ha; I Mohr
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

5.  Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer.

Authors:  T J Jorgensen; S Katz; E K Wittmack; S Varghese; T Todo; S D Rabkin; R L Martuza
Journal:  Neoplasia       Date:  2001 Sep-Oct       Impact factor: 5.715

Review 6.  Employing tumor hypoxia for oncolytic therapy in breast cancer.

Authors:  Yun Shin Chun; Prasad S Adusumilli; Yuman Fong
Journal:  J Mammary Gland Biol Neoplasia       Date:  2005-10       Impact factor: 2.673

7.  Tissue-specific transcriptional targeting of a replication-competent retroviral vector.

Authors:  Christopher R Logg; Aki Logg; Robert J Matusik; Bernard H Bochner; Noriyuki Kasahara
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

8.  Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide.

Authors:  Mark A Currier; Rebecca A Gillespie; Nancy M Sawtell; Yonatan Y Mahller; Greg Stroup; Margaret H Collins; Hirokazu Kambara; E Antonio Chiocca; Timothy P Cripe
Journal:  Mol Ther       Date:  2008-03-25       Impact factor: 11.454

9.  Regulation of herpes simplex virus 1 replication using tumor-associated promoters.

Authors:  John T Mullen; Hideki Kasuya; Sam S Yoon; Nancy M Carroll; Timothy M Pawlik; Soundararajalu Chandrasekhar; Hideo Nakamura; James M Donahue; Kenneth K Tanabe
Journal:  Ann Surg       Date:  2002-10       Impact factor: 12.969

10.  Developing novel oncolytic adenoviruses through bioselection.

Authors:  Wen Yan; Galila Kitzes; Farid Dormishian; Lynda Hawkins; Adam Sampson-Johannes; Josh Watanabe; Jenny Holt; Vivian Lee; Thomas Dubensky; Ali Fattaey; Terry Hermiston; Allan Balmain; Yuqiao Shen
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.